Recent trial data has shown that AstraZeneca’s Dapagliflozin cut the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo in patients with type II diabetes who had a prior heart attack. In a second pre-specified sub-analysis of data from the DECLARE-TIMI 58 study, the SGLT2 inhibitor reduced the relative risk of
Lilly have reported positive results from two Phase lll trials, PRONTO-T1D and PRONTO-T2D, which examined the safety and efficacy of Ultra Rapid Lispro (URLi) compared to insulin lispro to treat people with type 1 and type 2 diabetes. The trial met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to insulin lispro
AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of BMS-512148 compared to placebo for the treatment of patients with type 2 diabetes (T2D). The trial had met its primary safety objective of non-inferiority for major adverse cardiovascular events (MACE). The trial also achieved one of its two
Researchers at Lancaster University have identified a type 2 diabetes drug that has shown potential benefit in the treatment of Alzheimer’s disease. The treatment combined three older diabetes drugs to create a “triple agonist”, that combines GLP-1, GIP and glucagon. The belief being that boosting levels of growth hormones will aid in protecting the brain
Eli Lilly has announced that it will offer its insulin medication, at a 40% discount for eligible patients when purchased through the Blink Health app or website. Patients most likely to save on their purchase of insulin are those with no insurance or are in the deductible phase of their high-deductible insurance plans.
Lilly is hoping to launch 20 new molecular entities in the 2014 to 2023 timeframe, backed up by two new indications or line extensions each year, throughout its core therapeutic categories of diabetes, immunology, oncology, neurodegeneration and pain.
Diabetes is a common lifelong condition that is currently affecting the health of many people in the UK. It is estimated that there is currently 1 in 16 people living with the disease either diagnosed or undiagnosed. Under normal circumstances the pancreas produces insulin, a hormone that allows glucose to enter cells to be used
Eli Lilly and Boehringer Ingelheim’s Jardiance has become the first diabetes drug to show a significant reduction in cardiovascular deaths in a dedicated outcomes study. According to data* from the 7,000-plus patient trial EMPA-REG OUTCOME, Jardiance (empagliflozin) cut the risk of cardiovascular death by 38% when added to standard of care in type II diabetics
A three year partnership between AstraZeneca (AZ) and French National Institute of Health and Medical Research (Inserm) is aiming to advance the understanding of biological mechanisms that come with the conditions. Based on the findings, they hope to develop new therapeutic approaches to type 2 diabetes and chronic kidney disease.
Novo Nordisk has confirmed that they are investing around 750 million kroner (roughly equivalent to $130 million) on new diabetes laboratories at the R&D campus in Måløv, Denmark. Construction of the new laboratories has already started and the new facility, to be named the Diabetes Research House, will open in early 2016. The Diabetes Research
